Binding of valsartan to mammalian angiotensin AT1 receptors

The binding characteristics of the angiotensin AT1 receptor antagonist valsartan were investigated in different animal species and tissues. Using [125I](Sar1,Ile8) angiotensin II as radioligand, affinity constants were determined in liver and adrenal rat and marmoset, human adrenal and in rat aortic smooth muscle cells. In all tissues tested, valsartan had a greater affinity for the AT1 receptor than losartan (on average 5-fold). The affinities of both antagonists were up to 30 times weaker in the dog tissues [3H]Valsartan bound with high affinity (Kd 1.44 nmol/l) to the rat aortic smooth muscle cell AT1 receptor. Binding was saturable and reversible. Non-specific binding was low (10%). Reports that [3H]losartan binds to a non-angiotensin II binding site in rat liver and in other tissues could be confirmed. [3H]Valsartan on the other hand bound only to the AT1 receptor. Using a competition binding assay with [3H]losartan on rat liver membranes it could be shown that valsartan can bind to the 'losartan binding site', but at a 10,000-fold less affinity than for the AT1 receptor. Valsartan is therefore a highly specific and selective antagonist of the AT1 receptor. Due to its high affinity and low non-specific binding it is a suitable radioactive antagonist for the study of the distribution and function of the angiotensin AT1 receptor.

[1]  N. Iwai,et al.  Identification of two subtypes in the rat type I angiotensin II receptor , 1992, FEBS letters.

[2]  S. Whitebread,et al.  Localization of angiotensin II receptor subtypes in the rabbit heart. , 1995, Journal of molecular and cellular cardiology.

[3]  Steven Whitebread,et al.  Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series , 1994 .

[4]  N. Aiyar,et al.  Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor. , 1993, Journal of receptor research.

[5]  T. Schwartz,et al.  Mutations in transmembrane segment VIJ of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists , 1994, British journal of pharmacology.

[6]  J. Marie,et al.  Properties of [3H]LF 7-0156, a new nonpeptide antagonist radioligand for the type 1 angiotensin II receptor. , 1994, Molecular pharmacology.

[7]  H. Matsubara,et al.  Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. , 1995, The Journal of clinical investigation.

[8]  Yue Zhang,et al.  Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan. , 1994, The Journal of biological chemistry.

[9]  L. Burns,et al.  Molecular cloning of the canine angiotensin II receptor , 1994, FEBS letters.

[10]  A. Chiu,et al.  Characterization of angiotensin AT1A receptor isoform by its ligand binding signature , 1993, Regulatory Peptides.

[11]  S. Kuroda,et al.  Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression. , 1994, Biochemical and biophysical research communications.

[12]  S. Whitebread,et al.  Preliminary biochemical characterization of two angiotensin II receptor subtypes. , 1989, Biochemical and biophysical research communications.

[13]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .

[14]  H. Ishizaki,et al.  Inhibitory effect of the nonpeptide angiotensin II receptor antagonist losartan and its active metabolite, E-3174, on cAMP phosphodiesterase: additional action of the antagonists. , 1994, Biochemical pharmacology.

[15]  W. Greenlee,et al.  In vitro phamacology of MK‐996, a new potent and selective angiotensin II (AT1) receptor antagonist , 1994 .

[16]  D. Guo,et al.  Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. , 1992, Biochemical and biophysical research communications.

[17]  U. Steckelings,et al.  Angiotensin II Receptor Subtypes: Characterization, Signalling Mechanisms, and Possible Physiological Implications , 1993, Frontiers in Neuroendocrinology.

[18]  P. Widdowson,et al.  Binding of [3H]angiotensin II and [3H]DuP 753 (Losartan) to rat liver homogenates reveals multiple sites. Relationship to AT1a- and AT1b- type angiotensin receptors and novel nonangiotensin binding sites , 1993, Peptides.

[19]  A. Chiu,et al.  The ligand binding signatures of the rat AT1A, AT1B and the human AT1 receptors are essentially identical. , 1993, Biochemical and biophysical research communications.

[20]  S. Oparil,et al.  Blocking hypothalamic AT1 receptors lowers blood pressure in salt-sensitive rats. , 1992, Hypertension.

[21]  P. Timmermans,et al.  Proposed update of angiotensin receptor nomenclature. , 1995, Hypertension.

[22]  P. Halushka,et al.  1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. , 1991 .

[23]  S. Whitebread,et al.  Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype , 1993, British journal of pharmacology.

[24]  A. Chiu,et al.  [125I]EXP985: a highly potent and specific nonpeptide radioligand antagonist for the AT1 angiotensin receptor. , 1992, Biochemical and biophysical research communications.

[25]  B. Lévy,et al.  Differential regulation of angiotensin II and losartan binding sites in glomeruli and mesangial cells. , 1994, The American journal of physiology.

[26]  N. Aiyar,et al.  Cloning and characterization of a human angiotensin II type 1 receptor. , 1992, Biochemical and biophysical research communications.

[27]  M. Nakashima,et al.  Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. , 1993, British journal of clinical pharmacology.

[28]  S. Whitebread,et al.  Radioiodinated CGP 42112A: a novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors. , 1991, Biochemical and biophysical research communications.

[29]  R. Chang,et al.  Angiotensin receptor subtypes in rat, rabbit and monkey tissues: relative distribution and species dependency. , 1991, Life sciences.

[30]  R. Chang,et al.  Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand. , 1992, Molecular pharmacology.

[31]  L. Musgrove,et al.  Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. , 1992, Biochemical and biophysical research communications.

[32]  J. Murray,et al.  Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor , 1991, Nature.

[33]  S. Whitebread,et al.  Angiotensin II receptor subtypes and cardiac function. , 1994, European heart journal.

[34]  K. Catt,et al.  Regulation of Angiotensin II Receptors in Rat Brain During Dietary Sodium Changes , 1994, Hypertension.

[35]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[36]  R. Panek,et al.  Subclasses of angiotensin II binding sites and their functional significance. , 1990, Molecular pharmacology.

[37]  K. Grove,et al.  Angiotensin II and non-angiotensin II displaceable binding sites for [3H]losartan in the rat liver. , 1993, Biochemical pharmacology.

[38]  P. Timmermans,et al.  [3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype. , 1990, Biochemical and biophysical research communications.

[39]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[40]  D. Kerkman,et al.  [3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. , 1994, European journal of pharmacology.

[41]  E. Liu,et al.  DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. , 1992, Prostaglandins.

[42]  R D Smith,et al.  Angiotensin II receptor subtypes. , 1992, American journal of hypertension.

[43]  K. Catt,et al.  Novel angiotensin II antagonists distinguish amphibian from mammalian angiotensin II receptors expressed in Xenopus laevis oocytes. , 1991, Molecular pharmacology.

[44]  T. Schwartz,et al.  Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  K. Catt,et al.  Amphibian myocardial angiotensin II receptors are distinct from mammalian AT1 and AT2 receptor subtypes , 1991, FEBS letters.

[46]  L. Brown,et al.  ANGIOTENSIN RECEPTORS IN CARDIOVASCULAR DISEASES , 1994, Clinical and experimental pharmacology & physiology.

[47]  A. Egloff,et al.  Cloning, expression, and characterization of a gene encoding the human angiotensin II type 1A receptor. , 1992, Biochemical and biophysical research communications.